NCT06282185 2026-03-23
Superman
Canisius-Wilhelmina Hospital
Phase NA Withdrawn
Clinical Trials
20 trialsNCT04243473 2026-03-03
Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Withdrawn
NCT05014295 2026-02-24
Patient Recall of Cancer Screening and Diagnosis
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT03027986 2026-02-17
PROTOMEN
University Hospital, Rouen
Phase NA Withdrawn
NCT06881823 2025-12-29
NeoPSMA
Novartis
Phase 1/2 Withdrawn
NCT03274778 2025-11-18
Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
Oncology Institute of Southern Switzerland
Phase NA Withdrawn
NCT06060587 2025-10-22
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Northwestern University
Phase 2 Withdrawn
NCT04910425 2025-10-21
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT04645810 2025-10-15
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
University of Rochester
Phase NA Withdrawn
NCT05046782 2025-09-30
Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06527690 2025-09-29
REPRESENTATION
Latin American Cooperative Oncology Group
Phase 2 Withdrawn
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT02869282 2025-09-17
CHEMOPROST
Institut Bergonié
Withdrawn
NCT04580667 2025-08-28
Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity
DiaCarta, Inc.
Withdrawn
NCT04569461 2025-07-04
TALON
Duke University
Phase 2 Withdrawn
NCT05333432 2025-06-25
HRPCa-II
Assistance Publique - Hôpitaux de Paris
Phase NA Withdrawn
NCT03477864 2025-04-29
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
Thomas Jefferson University
Phase 1 Withdrawn
NCT06795178 2025-04-27
KATANA E3M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
NCT06795191 2025-04-27
KATANA E6M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
NCT03581500 2025-04-23
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn